Chloroquine

Chloroquine

Clinical data
ATC code	P01BA01 (WHO)
Pharmacokinetic data
Elimination half-life	1-2 months
Identifiers
IUPAC name N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine
CAS Number	54-05-7
PubChem CID	2719
DrugBank	APRD00468
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C18H26ClN3
Molar mass	319.872 g/mol

WikiDoc Resources for Chloroquine
Articles
Most recent articles on Chloroquine Most cited articles on Chloroquine Review articles on Chloroquine Articles on Chloroquine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Chloroquine Images of Chloroquine Photos of Chloroquine Podcasts & MP3s on Chloroquine Videos on Chloroquine
Evidence Based Medicine
Cochrane Collaboration on Chloroquine Bandolier on Chloroquine TRIP on Chloroquine
Clinical Trials
Ongoing Trials on Chloroquine at Clinical Trials.gov Trial results on Chloroquine Clinical Trials on Chloroquine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Chloroquine NICE Guidance on Chloroquine NHS PRODIGY Guidance FDA on Chloroquine CDC on Chloroquine
Books
Books on Chloroquine
News
Chloroquine in the news Be alerted to news on Chloroquine News trends on Chloroquine
Commentary
Blogs on Chloroquine
Definitions
Definitions of Chloroquine
Patient Resources / Community
Patient resources on Chloroquine Discussion groups on Chloroquine Patient Handouts on Chloroquine Directions to Hospitals Treating Chloroquine Risk calculators and risk factors for Chloroquine
Healthcare Provider Resources
Symptoms of Chloroquine Causes & Risk Factors for Chloroquine Diagnostic studies for Chloroquine Treatment of Chloroquine
Continuing Medical Education (CME)
CME Programs on Chloroquine
International
Chloroquine en Espanol Chloroquine en Francais
Business
Chloroquine in the Marketplace Patents on Chloroquine
Experimental / Informatics
List of terms related to Chloroquine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Chloroquine is a 4-aminoquinoline drug long used in the treatment or prevention of malaria. As it also mildly suppresses the immune system, it is used in some autoimmune disorders, such as rheumatoid arthritis and lupus erythematosus. After the malaria parasite Plasmodium falciparum started to develop widespread resistance to chloroquine, new potential utilisations of this cheap and widely available drug have been investigated. For example, chloroquine is in clinical trials as an investigational antiretroviral in humans with HIV-1/AIDS and as a potential antiviral agent against chikungunya fever. Moreover, the radiosensitizing and chemosensitizing properties of chloroquine are beginning to be exploited in anticancer strategies in humans.

Pharmacology

Chloroquine has a very high volume of distribution, as it diffuses into the body's adipose tissue. Chloroquine and related quinines have been associated with cases of retinal toxicity, particularly when provided at higher doses for longer time frames. Accumulation of the drug may result in deposits that can lead to blurred vision and blindness. With long term doses, routine visits to an optometrist or ophthalmologist are recommended.

Chloroquine is also a lysosomotropic agent, meaning that it accumulates preferentially in the lysosomes of cells in the body. The pKa for the quinoline nitrogen of chloroquine is 8.5, meaning that it is ~10% deprotonated at physiological pH as calculated by the Henderson-Hasselbalch equation. This decreases to ~0.2% at a lysosomal pH of 4.6. Because the deprotonated form is more membrane permeable than the protonated form, this results in a quantitative "trapping" of the compound in lysosomes.

(Note that a quantitative treatment of this phenomenon involves the pKas of all nitrogens in the molecule; this treatment, however, suffices to show the principle)

The lysosomotropic character of chloroquine is believed to account for much of its anti-malarial activity; the drug concentrates in the acidic food vacuole of the parasite and interferes with essential processes.

Malaria prevention

Chloroquine can be used for preventing malaria from Plasmodium vivax, ovale and malariae. Many areas of the world have widespread strains of chloroquine-resistant P. falciparum, so other antimalarials like mefloquine or atovaquone may be advisable instead. Combining chloroquine with proguanil may be more effective against chloroquine-resistant Plasmodium falciparum than treatment with chloroquine alone, but is no longer recommended by the CDC due to the availability of more effective combinations.

Doses

Per the Centers for Disease Control (CDC): Directions for Use The adult dosage is 500 mg chloroquine phosphate once a week. - Take the first dose of chloroquine 1 week before arrival in the malaria-risk area. - Take chloroquine once a week, on the same day of the week, while in the malaria-risk area. - Take chloroquine once a week for 4 weeks after leaving the malaria-risk area. Chloroquine should be taken on a full stomach to lessen nausea.

Chloroquine produced by Global Pharm is a white, round tablet with 7010 printed on one side. It is recommended that you do not chew the tablet, because it tastes horrible, and bitter.

Adverse effects

At the doses used for prevention of malaria, side effects include gastrointestinal problems such as stomach ache, itch, headache and blurred vision. When doses are extended over a number of months it is important to watch out for a slow onset of "changes in moods" (i.e.depression, anxiety). These may be more pronounced with higher doses used for treatment. Chloroquine tablets have an unpleasant metallic taste.

A serious side effect is also a rare toxicity in the eye (generally with chronic use), and requires regular monitoring even when symptom-free. The daily safe maximum doses for eye toxicity can be computed from one's height and weight using this calculator. The use of Chloroquine has also been associated with the development of Central Serous Retinopathy.

Chloroquine is very dangerous in overdose. It is rapidly absorbed from the gut and death often occurs within 2½ hours of taking the drug. The therapeutic index for chloroquine is small and just doubling the normal dose of chloroquine can be fatal.

Mechanism of action

Inside the red blood cells, the malarial parasite must degrade the hemoglobin for the acquisition of essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. This is essential for parasitic growth and division inside the red blood cell. It is carried out in the digestive vacuole of the parasite cell.

During this process, the parasite produces the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite polymerizes heme to form hemozoin, a non-toxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals.

Chloroquine enters the red blood cell, inhabiting parasite cell, and digestive vacuole by simple diffusion. Chloroquine then becomes protonated (to CQ2+) as the digestive vacuole is known to be acidic (pH 4.7), chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further polymerization of heme, thus leading to heme build up. Chloroquine binds to heme (or FP) to form what is known as the FP-Chloroquine complex, this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-Chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. In essence, the parasite cell drowns in its own metabolic products.

The effectiveness of chloroquine against the parasite has declined as resistant strains of the parasite evolved which effectively neutralized the drug via mechanism that drains chloroquine away from the digestive vacuole. CQ-Resistant cells efflux chloroquine at 40 times the rate of CQ-Sensitive cells, this is related to a number of mutations that trace back to transmembrane proteins of the digestive vacuole, including an essential mutation in the PfCRT gene (Plasmodium falciparum Chloroquine Resistance Transporter). This mutated protein may actively pump chloroquine from the cell. Resistant parasites frequently have mutated products or amplified expression of ABC transporters that pump out the chloroquine, typically PfMDR1 and PfMDR2 (Plasmodium falciparum Multi-Drug Resistance genes). Resistance has also been conferred by reducing the lower transport activity of the intake mechanism, so less chloroquine is imported into the parasite[2].

Research on the mechanism of chloroquine and how the parasite has acquired chloroquine resistance is still ongoing, and this article is not by any means fact. Other theories of chloroquine's mechanism of action suggest DNA intercalation or a combination of the disrupted membrane function of the lysosome.

Against rheumatoid arthritis, it operates by inhibiting lymphocyte proliferation, phospholipase A, release of enzymes from lysosomes, release of reactive oxygen species from macrophages, and production of IL-1.

As an antiviral agent, it impedes the completion of the viral life cycle by inhibiting some processes occurring within intracellular organelles and requiring a low pH. As for HIV-1, chloroquine inhibits the glycosylation of the viral envelope glycoprotein gp120, which occurs within the Golgi apparatus.

The mechanisms behind the effects of chloroquine on cancer are currently being investigated. The best know effects (investigated in clinical and pre-clinical studies) include radiosensitising effects through lysosome permeabilisation, and chemosensitising effects through inhibition of drug efflux pumps (ATP-binding cassette transporters)or other mechanisms (reviewed in the second-to-last reference below).

References

• Plowe CV. Antimalarial drug resistance in Africa: strategies for monitoring and deterrence. Curr Top Microbiol Immunol. 2005;295:55-79.
• Uhlemann AC, Krishna S. Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr Top Microbiol Immunol. 2005;295:39-53.
• Identification of a chloroquine importer in Plasmodium falciparum. Differences in import kinetics are genetically linked with the chloroquine-resistant phenotype. J Biol Chem. 1997 Jan 31;272(5):2652-8.
• Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006 Aug;12(4):294-304.
• Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003 Nov;3(11):722-7.
• Savarino A, Lucia MB, Giordano F, Cauda R. Risks and benefits of chloroquine use in anticancer strategies. Lancet Oncol. 2006 Oct;7(10):792-3.
• Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006 Mar 7;144(5):337-43. Summary for patients in: Ann Intern Med. 2006 Mar 7;144(5):I31.

External links

• Chloroquine Anti-HIV action

Template:WS